torezolid

In December 2010, research was published elucidating the mechanism by which an investigational second generation oxazolidinone called torezolid phosphate retains full activity against clinical isolates of Staphylococcus aureus carrying the cfr gene.

unknown title 2011

TSRX - News) announced today that the Company has completed the enrollment of the first of two planned Phase 3 trials of tedizolid phosphate (formerly known as torezolid phosphate) in the study of acute bacterial skin and skin structure infections (ABSSSI).

unknown title 2011

Trius Therapeutics TSRX said today it had come to an agreement with the US Food and Drug Administration on the design of a second phase 3 study for torezolid phosphate.

Trius Therapeutics Reaches Deal For New Study 2011

Trius Therapeutics TSRX said today it had come to an agreement with the US Food and Drug Administration on the design of a second phase 3 study for torezolid phosphate.

Trius Therapeutics Reaches Deal For New Study 2011

Ms. Bayko says the stock was hurt because Trius wasn't going to be able to provide any Phase III clinical-trial data on its antibiotic, torezolid, until the beginning of 2012.

Pharmaceuticals 2011

Based in San Diego, Trius Therapeutics is a biopharmaceutical company focused on the developing its first drug, torezolid phosphate, for the treatment of serious infections that include methicillin-resistant Staphylococcus aureus, or MRSA.

Trius Closes Flat After Cutting IPO Price 2010

The potent activity of torezolid against cfr-positive bacteria differentiates it from linezolid, marketed by Pfizer as ZyvoxR, which is ineffective against cfr-positive strains.

unknown title 2011

In addition to the company's torezolid phosphate clinical program, it is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria.

unknown title 2011

"I look forward to joining this exciting company, leading the commercialization of torezolid phosphate into a successful anti-infective drug and creating value for our customers and shareholders."

Trius Hires Chief Commercial Officer - Yahoo! Finance 2011

The company's lead investigational drug, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI, the first such trial to be initiated under a Special Protocol Assessment SPA.

unknown title 2011